Dyne Therapeutics (DYN) Appoints Barry Greene to Board of Directors

Dyne Therapeutics (DYN) announced the appointment of Barry Greene to its Board of Directors, effective June 23, 2026. Greene's addition is expected to leverage his extensive experience in biopharmaceutical leadership, strategic development, and commercialization to guide the company's therapeutic pipeline. Greene previously served as President and CEO of Sage Therapeutics, where he led the company through its IPO and the launch of its first commercial product. His career also includes executive positions at Alnylam Pharmaceuticals and MedImmune. Dyne Therapeutics focuses on advancing its FORCE platform to develop treatments for rare neuromuscular diseases.